These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 26610710)

  • 1. Alzheimer disease. Could anti-amyloid-β immunotherapy do more harm than good?
    Wood H
    Nat Rev Neurol; 2016 Jan; 12(1):2. PubMed ID: 26610710
    [No Abstract]   [Full Text] [Related]  

  • 2. Decreased amyloid-β and increased neuronal hyperactivity by immunotherapy in Alzheimer's models.
    Busche MA; Grienberger C; Keskin AD; Song B; Neumann U; Staufenbiel M; Förstl H; Konnerth A
    Nat Neurosci; 2015 Dec; 18(12):1725-7. PubMed ID: 26551546
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mouse models reveal why Alzheimer's treatment fails.
    Niemeyer JE
    Lab Anim (NY); 2016 Apr; 45(4):125. PubMed ID: 27003340
    [No Abstract]   [Full Text] [Related]  

  • 4. Active and passive Abeta-immunotherapy: preclinical and clinical studies and future directions: part I.
    Agadjanyan MG; Cribbs DH
    CNS Neurol Disord Drug Targets; 2009 Mar; 8(1):1-6. PubMed ID: 19275632
    [No Abstract]   [Full Text] [Related]  

  • 5. Amyloid-beta immunotherapy: the hope for Alzheimer disease?
    Barrera-Ocampo A; Lopera F
    Colomb Med (Cali); 2016 Dec; 47(4):203-212. PubMed ID: 28293044
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of Alzheimer's disease: the beginning of a new era.
    Schenk D
    Curr Alzheimer Res; 2006 Jul; 3(3):177. PubMed ID: 16842091
    [No Abstract]   [Full Text] [Related]  

  • 7. [Adaptive immunity to Aβ amyloid peptide in Alzheimer's disease: lessons and perspectives].
    Dorothée G; Aucouturier P
    Med Sci (Paris); 2011 Nov; 27(11):938-40. PubMed ID: 22130019
    [No Abstract]   [Full Text] [Related]  

  • 8. Improved Brain Expression of Anti-Amyloid β scFv by Complexation of mRNA Including a Secretion Sequence with PEG-based Block Catiomer.
    Perche F; Uchida S; Akiba H; Lin CY; Ikegami M; Dirisala A; Nakashima T; Itaka K; Tsumoto K; Kataoka K
    Curr Alzheimer Res; 2017; 14(3):295-302. PubMed ID: 27829339
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amyloid immunotherapy-engendered CNS inflammation.
    Bowers WJ; Federoff HJ
    Neurobiol Aging; 2002; 23(5):675-6; discussion 683-4. PubMed ID: 12392770
    [No Abstract]   [Full Text] [Related]  

  • 10. [Current trend of immunotherapy for Alzheimer's disease].
    Matsumoto SE; Tabira T
    Nihon Rinsho; 2011 Sep; 69(9):1628-32. PubMed ID: 21922765
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alzheimer's amyloid immunotherapy: quo vadis?
    Gandy S; Heppner FL
    Lancet Neurol; 2005 Aug; 4(8):452-3. PubMed ID: 16033686
    [No Abstract]   [Full Text] [Related]  

  • 12. beta-peptide immunization: a possible new treatment for Alzheimer disease.
    Schenk DB; Seubert P; Lieberburg I; Wallace J
    Arch Neurol; 2000 Jul; 57(7):934-6. PubMed ID: 10891974
    [No Abstract]   [Full Text] [Related]  

  • 13. Combined treatment of amyloid-β₁₋₄₂-stimulated bone marrow-derived dendritic cells plus splenocytes from young mice prevents the development of Alzheimer's disease in APPswe/PSENldE9 mice.
    Wang F; Liu H; Shen X; Ao H; Moore N; Gao L; Chen L; Hu H; Ma H; Yang Z; Zhai C; Qin J; Zhou G; Peng Y; Feng X; Li R; Liang C
    Neurobiol Aging; 2015 Jan; 36(1):111-22. PubMed ID: 25085784
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A beta immunotherapy: Lessons learned for potential treatment of Alzheimer's disease.
    Schenk DB; Seubert P; Grundman M; Black R
    Neurodegener Dis; 2005; 2(5):255-60. PubMed ID: 16909006
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alzheimer disease: Lessons from immunotherapy for Alzheimer disease.
    Wang YJ
    Nat Rev Neurol; 2014 Apr; 10(4):188-9. PubMed ID: 24638135
    [No Abstract]   [Full Text] [Related]  

  • 16. Lessons from Anti-Amyloid-β Immunotherapies in Alzheimer Disease: Aiming at a Moving Target.
    Wang Y; Yan T; Lu H; Yin W; Lin B; Fan W; Zhang X; Fernandez-Funez P
    Neurodegener Dis; 2017; 17(6):242-250. PubMed ID: 28787714
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Beta-amyloidbased immunotherapy as a treatment of Alzheimers disease.
    Solomon B
    Drugs Today (Barc); 2007 May; 43(5):333-42. PubMed ID: 17724499
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibody against C-terminal Abeta selectively elevates plasma Abeta.
    Gray AJ; Sakaguchi G; Shiratori C; Becker AG; LaFrancois J; Aisen PS; Duff K; Matsuoka Y
    Neuroreport; 2007 Feb; 18(3):293-6. PubMed ID: 17314674
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Translating research on brain aging into public health: a new type of immunotherapy for Alzheimer's disease.
    Lannfelt L; Pettersson FE; Nilsson LN
    Nutr Rev; 2010 Dec; 68 Suppl 2():S128-34. PubMed ID: 21091946
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunotherapy for Alzheimer's disease.
    Wang W; Fan L; Xu D; Wen Z; Yu R; Ma Q
    Acta Biochim Biophys Sin (Shanghai); 2012 Oct; 44(10):807-14. PubMed ID: 22899646
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.